← Eichor
Condition: Relapsed Sarcomas Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Relapsed Sarcomas

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
Phase 2 · 11 location(s) · Hansoh BioMedical R&D Company · NCT05830123VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Phase 1/Phase 2 · 7 location(s) · University of Texas Southwestern Medical Center · NCT04796012cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Phase N/A · 17 location(s) · Adela, Inc · NCT05366881Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Phase 1 · 1 location(s) · Case Comprehensive Cancer Center · NCT05210374Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
NA · 16 location(s) · Centre Leon Berard · NCT04055220Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Phase 1 · 1 location(s) · Stanford University · NCT06500819GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Phase 1 · 2 location(s) · Canadian Cancer Trials Group · NCT07297667Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Phase 1 · 1 location(s) · Emory University · NCT06492954Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL
Phase 2 · 7 location(s) · University Medical Center Groningen · NCT05641428Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas
Phase N/A · 10 location(s) · Azienda Ospedaliera Ospedale Infantile Regina Margherita San · NCT04621201Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma
Phase 2 · 2 location(s) · Hackensack Meridian Health · NCT05726383A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06736613Actinium Therapy for Late-stage Aggressive Sarcomas
Phase 1 · 6 location(s) · Ratio Therapeutics, Inc. · NCT07156565Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Diseas
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05907759A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherap
Phase 1/Phase 2 · 22 location(s) · Nationwide Children's Hospital · NCT05634369Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Phase 1/Phase 2 · 15 location(s) · Jazz Pharmaceuticals · NCT05734066Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Phase 1/Phase 2 · 1 location(s) · University of Washington · NCT04797767Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Phase 1/Phase 2 · 12 location(s) · Milton S. Hershey Medical Center · NCT06465199Losartan + Sunitinib in Treatment of Osteosarcoma
Phase 1 · 4 location(s) · University of Colorado, Denver · NCT03900793Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treat
Phase 1/Phase 2 · 1 location(s) · Fundación de investigación HM · NCT06607692Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Phase 2 · 3 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT01804634A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / R
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07548697A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax,
Phase 1 · 44 location(s) · Kura Oncology, Inc. · NCT05735184Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adol
Phase 1/Phase 2 · 3 location(s) · David S Shulman, MD · NCT06709495Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relap
Phase 2 · 1 location(s) · Australasian Leukaemia and Lymphoma Group · NCT06287398Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy
Phase N/A · 1 location(s) · Incyte Biosciences Italy S.r.l · NCT06299553CAR-T Followed by Bispecific Antibodies
Phase 2 · 2 location(s) · Abramson Cancer Center at Penn Medicine · NCT04889716Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
Phase 1 · 4 location(s) · Children's Hospital of Philadelphia · NCT06156410Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/
Phase 1 · 1 location(s) · Emory University · NCT05400603
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.